Characterising the urinary acylcarnitine and amino acid profiles of HIV/TB co-infection, using LC-MS metabolomics.
Charles PretoriusLaneke LuiesPublished in: Metabolomics : Official journal of the Metabolomic Society (2024)
The metabolic profiling of HIV/TB co-infection highlights the profound impact of TB on metabolic pathways, which may exacerbate the clinical complexities of co-infection. Understanding these metabolic disruptions can guide the development of targeted treatments and improve management strategies, ultimately enhancing the clinical outcomes for these patients. Further research is required to validate these findings and explore their implications in larger, diverse populations.
Keyphrases
- mycobacterium tuberculosis
- antiretroviral therapy
- hiv positive
- human immunodeficiency virus
- hiv infected
- hepatitis c virus
- hiv testing
- end stage renal disease
- amino acid
- hiv aids
- ejection fraction
- newly diagnosed
- prognostic factors
- mass spectrometry
- men who have sex with men
- intellectual disability
- single cell
- cancer therapy
- drug delivery
- genetic diversity